No­vo Nordisk’s US semaglu­tide man­u­fac­tur­ing site un­der the spot­light again as 2022 mon­i­tor­ing is­sue sur­faces

No­vo Nordisk’s US fa­cil­i­ty has had at least four qual­i­ty con­trol is­sues re­lat­ed to mi­crobes in the past two years. Its Clay­ton, NC site man­u­fac­tures the com­pa­ny’s ac­tive phar­ma­ceu­ti­cal in­gre­di­ent semaglu­tide, used in its block­buster di­a­betes and weight loss drugs.

Man­u­fac­tur­ing con­cerns sur­round­ing “ob­jec­tion­able or­gan­isms” first came to light on Mon­day, when Mar­ket Wire re­port­ed the com­pa­ny re­ceived a Form 483 which de­tailed is­sues on three sep­a­rate oc­ca­sions this year. A fourth in­stance, as re­port­ed by Reuters on Wednes­day, notes a sim­i­lar is­sue in May 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER